Viewing Study NCT03552393


Ignite Creation Date: 2025-12-25 @ 1:09 AM
Ignite Modification Date: 2026-03-27 @ 2:22 PM
Study NCT ID: NCT03552393
Status: COMPLETED
Last Update Posted: 2022-03-07
First Post: 2018-04-27
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.
Sponsor: Hoffmann-La Roche
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Anemia View
None Renal Insufficiency, Chronic View
Keywords: